GENELUX CORP
GNLXNASDAQ🏆 #3969 by market capEarnings Nov 2US Equity
$2.16▼ $0.07 (−2.93%)
Latest quoteTrack GNLX
Get earnings, price moves & breaking news on Telegram
24h▼ 2.9%
7d▲ 9.4%
14d▼ 12.8%
30d▼ 12.0%
ytd▼ 50.5%
1y▼ 71.9%
🏦Market Cap
$98M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
12499.0x
Expensive
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $2.15 – $2.18
- 52-Week Range
- $1.86 – $8.54
- Volume (shares)
- 1,563
- Avg Volume (shares)
- —
- Shares Outstanding
- 45.3M
- Next Earnings
- 2026-11-02
Fundamentals Snapshot
- Annual Revenue
- $8,000
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- 12499.0x
- EPS (TTM)
- $-0.87
- Dividend Yield
- —
- Dilution (1yr)
- +18.2%
GENELUX CORP
GNLXFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$8K▲ +0.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-7075.0%▼ −36.8% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$33M▲ +4.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$26M▲ +22.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
37.2M▲ +18.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$4M▼ −$3M YoY
StockOtter · stockotter.spaceAbout GENELUX CORP
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
11 analysts
Strong Buy2
Buy8
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.